Table III.
Reported cases and characteristics of PPG in urine-carrying ostomies
| Case | Age, sex | Time to ulcer onset | Underlying disease | Stoma type | Biopsy | Effective treatment (time to resolution) |
|---|---|---|---|---|---|---|
| 0∗ | 70, M | 1 mo | Bladder cancer | Ileal loop urinary diversion | Granulation tissue | Surgical debridement and closure followed by wound care (10 mo)† |
| 19 | 83, M | 20 y | Bladder cancer | Urostomy | Nonspecific inflammatory infiltrate | Triamcinolone acetonide, topical clobetasol (1.5 mo) |
| 29 | 73, M | 11 mo | Bladder cancer | Urostomy | Nonspecific inflammatory infiltrate | 1st occurrence: dapsone (11 mo) 2nd occurrence: mycophenolate mofetil (8 mo) |
| 310 | 45, F | 5 wk | Neurogenic bladder | Urostomy | Granulation tissue | Tacrolimus 0.3% in carmellose sodium paste (1 mo) |
| 410 | 57, F | 1 y | Bladder cancer | Urostomy | Granulation tissue | Minocycline twice daily while weaning the patient’s dose of daily prednisolone from 30 mg to 0 mg (1.5 mo) |
| 510 | 57 F | 3 y | Neurogenic bladder | Urostomy | Not performed | 2 months of no treatment followed by clobetasol propionate 0.05% for 2 weeks (2.5 mo) |
PPG, Peristomal pyoderma gangrenosum.
∗
Denotes the patient in our case report.
†
Extent of improvement shown in Fig 1, B. Wound care regimen: silver sulfate foam bandages, sodium chlor-hypochlorous acid 0.033% solution, and daily collagenase ointment.